SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-063369
Filing Date
2023-11-14
Accepted
2023-11-14 08:15:08
Documents
14
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apvo-20231114.htm   iXBRL 8-K 48172
2 EX-99.1 apvo-ex99_1.htm EX-99.1 280105
3 GRAPHIC img237228349_0.jpg GRAPHIC 4584
  Complete submission text file 0000950170-23-063369.txt   470307

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT apvo-20231114.xsd EX-101.SCH 2487
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT apvo-20231114_lab.xml EX-101.LAB 14028
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT apvo-20231114_pre.xml EX-101.PRE 10302
8 EXTRACTED XBRL INSTANCE DOCUMENT apvo-20231114_htm.xml XML 4925
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Filer) CIK: 0001671584 (see all company filings)

IRS No.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37746 | Film No.: 231401699
SIC: 2834 Pharmaceutical Preparations